Cannabigerovarin CBGV CAS: 55824-11-8

CAS NO: 55824-11-8
Cannabigerovarin CBGV
Chemical Name: Cannabigerovarol
Molecular Formula: C19H28O2
Formula Weight: 288.42
CAS No.: 55824-11-8
Description Review
Description

Cannabigerovarin (CBGV) is a minor cannabinoid found in cannabis plants. It is similar to other cannabinoids like THC and CBD, but with some distinct differences that make it potentially beneficial for various health conditions. In this article, we will explore the chemical properties, health benefits, potential effects, safety profile, dosing information, and more about CBGV.

Introducing CBGV:

CBGV is a naturally occurring phytocannabinoid found in various strains of the cannabis plant. It was first discovered in the 1960s, but its potential therapeutic properties have only recently been explored.

Chemical name:

The chemical name of CBGV is 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzenediol.

Molecular formula:

The molecular formula of CBGV is C21H32O2.

Formula weight:

The formula weight of CBGV is 316.49 g/mol.

CAS No:

The CAS number of CBGV is 55824-11-8.

Top ten keywords from Google and Synonyms:

  1. Cannabigerovarin
  2. CBGV oil
  3. Non-psychoactive cannabinoid
  4. Anti-inflammatory properties
  5. Antioxidant effects
  6. Pain management
  7. Anxiety relief
  8. Apoptosis inducer
  9. Cannabis extract
  10. Phytocannabinoid

Health benefits of CBGV:

CBGV has several potential health benefits based on preliminary research. Here are some of the most promising health benefits of CBGV:

  1. Anti-inflammatory: CBGV has been shown to have significant anti-inflammatory effects, making it potentially useful for treating conditions like arthritis and inflammatory bowel disease.

  2. Antioxidant: CBGV may also have antioxidant properties, which means it could help protect the body from damage caused by free radicals.

  3. Pain relief: CBGV has been shown to have analgesic effects, making it potentially useful for treating chronic pain conditions.

Potential effects:

Although CBGV is not psychoactive, it can still have potential effects on users. For example, CBGV may cause drowsiness or fatigue, especially when taken in high doses. Additionally, CBGV may interact with certain medications, so it's important to talk to your doctor before using CBGV if you are taking any prescription drugs.

Product mechanism:

Like other cannabinoids, CBGV works by interacting with the body's endocannabinoid system (ECS). The ECS is a complex network of receptors and chemicals that help regulate many physiological processes, including mood, appetite, pain, and inflammation. CBGV is thought to work by binding to certain receptors in the brain and body, although the exact mechanisms are not yet fully understood.

Safety:

CBGV is generally considered safe for human consumption, although more research is needed to determine its long-term safety profile. Some users may experience side effects, such as drowsiness, dry mouth, or mild gastrointestinal discomfort, but these are generally mild and temporary. As with any supplement, it's important to talk to your doctor before using CBGV.

Side effects:

CBGV has few reported side effects. However, some users may experience mild drowsiness, dry mouth, or gastrointestinal discomfort. These side effects are generally mild and temporary and should subside after discontinuing use.

Dosing information:

There is currently no official dosing recommendation for CBGV, as more research is needed to determine the optimal dose for different uses. However, most CBGV products come in standard doses ranging from 5-50mg per serving. It's important to start with a low dose and gradually increase as needed, under the guidance of a healthcare professional.

Conclusion:

CBGV is a promising cannabinoid that has several potential health benefits, including anti-inflammatory, antioxidant, and pain-relieving properties. Although more research is needed to fully understand its effects, CBGV has a good safety profile and is generally considered safe for human consumption. If you're interested in trying CBGV, talk to your doctor to determine if it's right for you and to discuss appropriate dosing and monitoring

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code